As the life sciences industry continues to grow in complexity, its commercial model is changing too. The traditional ’single message to many’ approach to delivering your product information has been re-focused to building and maintaining relationships to achieve lasting share of mind. Given the imperative to ‘do more with less’ your commercial organization may be re-evaluating the effectiveness of your Customer Relationship Management (CRM) system. What are the questions that you should be asking yourself and your vendor when considering a CRM investment? Please join us for a free live webcast, featuring a panel of industry experts who will share practical insights to help you define your organization?s current and future needs and determine what CRM capabilities are best suited meet them.

Register Free at http://pharmexec.com/yourcrm

Sponsor:
Cegedim Dendrite

This event focuses on our Clinical Trials solution with HighPoint Solutions and is designed to illustrate how pharma companies can reduce the risk and expense of the clinical trial process with better use of data. Attend this Web seminar to understand how pharmaceutical manufacturers can obtain a clear and consistent view of clinical-trial progress and costs through effective data governance – providing a platform for future growth.

Register Free at http://pharmexec.com/clinicaloperations

Sponsor by Kalido

Guest blog by W Scott Evangelista, principal, Deloitte Consulting LLP

Without committed leadership from the top of an organization, the best answers will not find the light of day, and the “my number is better than yours” issue will persist. The shackles of the past (standard reports with standard data) will inevitably bind companies to increasingly failing strategies. I believe it is time leadership embraces predictive modeling to enable better decision making.

So many companies when faced with gradual market shifts and increasing competition or strengthening barriers keep turning to old solutions and don’t recognize they are in the midst of new problems. Leadership with many companies react so slowly to change that the companies are often in dire straits before the mandate for change comes…usually from the newly appointed CEO.

The one advantage pharmaceutical companies have in leveraging predictive analytics is that most of them are so far behind the state of what is possible that they can learn quickly from other industries and adopt tested technologies to facilitate their rapid adoption.

If pharmaceutical leadership is not investing today in building robust capabilities in predictive analytics, they will soon be looking to leverage their vast experience on the lecture circuit.  Leadership needs to embrace the notion that analytics can help them create and find insights that will yield competitive advantage, and even if they don’t embrace it, they should at least be willing to do robust tests of the concept. In many ways, companies have been outsourcing these capabilities for years to vendors that do very robust statistical modeling and make recommendations on how resources should be allocated. This results in many companies getting the same advice (most use the same few vendors) and having no meaningful advantage.

It’s time for a change, the lecture circuit isn’t that interesting.

To hear other perspectives on how business analytics can be leveraged for a strategic advantage, you might want to check out the recent Pharm Exec Webcast in which I  participated on a panel Daniel Feldman of the Pharmaceutical Management Science Association, and SAS’s Patrick Homer.

As we all know, the industry is facing trends that will continue to erode profitability if the sales and marketing model does not change. The image of a new commercial model is now starting to emerge – and although the details are far from clear, the basic components are there in terms of some of the things that the industry needs to achieve.

One of the trends in the new commercial model is for companies to make smarter sales and marketing decisions based on deeper analytical insights—and to develop these competencies in house to create a clear and distinct competitive advantage. Organizations that use business analytics today drive value and better decisions across the business—and those that make the better decisions now are the ones who will ultimately succeed in the new commercial model. The Webcast will help corporate decision makers like you better understand why transformational business analytics is a game changer for Pharma that will:

* Uncover real intelligence within your organization.
* Solve complex business problems.
* Help you understand who your high-value customers are.
* Create a clear and distinct competitive advantage.
* Drive sustainable growth through innovation.

Register Free at www.pharmexec.com/businessanalytics

More companies are starting to focus on their laboratory assets, how these are maintained, how validation is carried out, how downtime affects their operations and scientists’ productivity, how those assets are being utilized and whether they have over/under capacity.

Our lifecycle asset management programs go well beyond asset maintenance and provide you with a future proof solution that will improve scientist productivity, support capital investment strategies, help drive efficiency through multiple functions without compromising quality or scientist experience.

Register Free at www.pharmexec.com/datadriven

Sponsor:
GE Healthcare

The mere mention of the term “comparative effectiveness” evokes a host of reactions among pharmaceutical manufacturers: confusion, skepticism, even fear. With President Obama calling for a national agency for comparative effectiveness, no one doubts that it is coming to healthcare—but what will it encompass? How will comparative effectiveness impact access to medications? What can manufacturers do to prepare?

Join us on Thursday, June 25 at 2:00 PM (EDT), as Tommy Bramley, senior director for Xcenda, and Tracy Foster, president for Lash Group, present insights that address:

• An overview of comparative effectiveness and an update of its
  progress at the federal level
• Perspectives about comparative effectiveness from managed
  care stakeholders
• How manufacturers can evaluate their risk and prepare for additional
  requests for comparative analysis data
• What manufacturers can do to ensure continued patient access
  to products
• How manufacturers can validate ongoing clinical and economic
  benefits for their products

Register for this FREE Webcast!